Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.63 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8090078 | 0.85 | EGFR (0.48) | EGFRHTTCSF1RERBB2CYP1A2 | |
| SCHEMBL31053046 | 0.85 | EGFR (0.60) | EGFRHTTMAP3K14CSF1RNPSR1 | |
| Hydrochloric Acid SCHEMBL8646103 | 0.84 | EGFR (0.47) | EGFRHTTCSF1RERBB2CYP1A2 | |
| SCHEMBL7122346 | 0.82 | EGFR (0.60) | EGFRHTTMAP3K14CSF1RNPSR1 | |
| SCHEMBL9056703 | 0.80 | EGFR (0.73) | EGFRCSF1RPDGFRBKDR | |
| Hydrochloric Acid SCHEMBL8652234 | 0.79 | EGFR (0.74) | EGFRCSF1RERBB2PDGFRBKDR | |
| SCHEMBL7129018 | 0.78 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL30964509 | 0.77 | EGFR (0.52) | EGFRHTTCSF1RNPSR1ALDH1A1 | |
| SCHEMBL8644637 | 0.76 | EGFR (0.75) | EGFRCSF1RPDGFRBKDR | |
| SCHEMBL8081981 | 0.76 | EGFR (0.55) | EGFRHTTCSF1RALDH1A1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885HTT 2086/4885MAP3K14 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.